Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. (Beixin Life) is set to undergo its IPO review on July 18, marking it as the second pharmaceutical company to utilize the fifth set of standards for listing on the Sci-Tech Innovation Board [1][3] Group 1: Company Overview - Beixin Life focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [3] - The company is recognized as a national high-tech enterprise and aims to provide transformative solutions for cardiovascular disease treatment [3] Group 2: IPO Progress - Beixin Life's IPO journey began with acceptance on March 30, 2023, followed by an inquiry phase starting on April 24, 2023 [3] - The IPO process faced a halt due to tightened review standards but resumed after the China Securities Regulatory Commission announced the restart of the fifth set of standards [3][10] - The company disclosed its second round of inquiry responses on July 8, 2023, and received the opportunity for the IPO review on July 11, 2023 [3] Group 3: Financial Performance - Beixin Life reported continuous net losses during the reporting period, with revenues of approximately 92.45 million yuan, 184 million yuan, and 317 million yuan for the years 2022, 2023, and 2024 respectively [3] - Corresponding net losses were approximately -290 million yuan, -140 million yuan, and -43.6 million yuan, showing a trend of reduced losses year over year [3] Group 4: Market Context - There are currently five pharmaceutical companies, including Beixin Life, queuing for IPOs under the fifth set of standards on the Sci-Tech Innovation Board [5] - He Yuan Bio is noted as the first company to pass the review under the restarted fifth set of standards, with others like Si Zhe Rui and Bi Bei Te also in the registration phase [6][10] - The fifth set of standards aims to support innovative pharmaceutical companies that are not yet profitable but possess core technologies and market potential [10]

益)扣除相关费用和信用减值损失后的余额，本期利润为本期已实现收益加上本期公允价值 变动收益； 第 2 页 共 13 页 招商国证生物医药指数证券投资基金 基金管理人：招商基金管理有限公司 基金托管人：中国银行股份有限公司 送出日期：2025 年 7 月 18 日 招商国证生物医药指数证券投资基金 2025 年第 2 季度报告 §1 重要提示 基金管理人的董事会及董事保证本报告所载资料不存在虚假记载、误导性陈述或重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 基金托管人中国银行股份有限公司根据本基金合同规定，于 2025 年 7 月 17 日复核了本 报告中的财务指标、净值表现和投资组合报告等内容，保证复核内容不存在虚假记载、误 导性陈述或者重大遗漏。 基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资产，但不保证基金一 定盈利。 基金的过往业绩并不代表其未来表现。投资有风险，投资者在作出投资决策前应仔细 阅读本基金的招募说明书。 本报告中财务资料未经审计。 本报告期自 2025 年 4 月 1 日起至 6 月 30 日止。 §2 基金产品概况 基金简称 招商国证生物医药指数 场内简称 ...

Group 1 - The Hang Seng Index fell by 0.08% on July 17, with southbound trading totaling HKD 134.72 billion, including HKD 68.29 billion in buying and HKD 66.43 billion in selling, resulting in a net inflow of HKD 1.85 billion [1] - The southbound trading through Stock Connect (Shenzhen) had a total turnover of HKD 49.60 billion, with net buying of HKD 0.19 billion, while Stock Connect (Shanghai) had a turnover of HKD 85.12 billion, with net buying of HKD 1.67 billion [1] - The most actively traded stock by southbound funds was Xiaomi Group-W, with a total turnover of HKD 64.88 billion, followed by Alibaba-W and Guotai Junan International with turnovers of HKD 52.03 billion and HKD 50.25 billion respectively [1] Group 2 - Among the stocks with net buying, Meituan-W led with a net inflow of HKD 6.06 billion, while China Construction Bank and Xiaomi Group-W followed with net inflows of HKD 5.91 billion and HKD 3.15 billion respectively [1][2] - The stock with the highest net selling was Pop Mart, with a net outflow of HKD 8.44 billion, and Tencent Holdings and Kangfang Biotech also experienced significant net selling of HKD 3.79 billion and HKD 0.76 billion respectively [1][2] - Meituan-W has seen continuous net buying for 9 days, with a total net inflow of HKD 72.14 billion during this period [2]

Investment Rating - The industry investment rating is "Positive" and maintained [11] Core Insights - The innovation chain in China's pharmaceutical industry is gradually improving, with a new cycle of investment in innovative drug research and development expected to begin [10][44] - The financing amount for China's biopharmaceutical sector is likely to rebound from its lowest point, supported by government policies and the establishment of regional investment funds [6][23] - The IPO channels for innovative drugs are widening, with significant fundraising for research and development from both Hong Kong and A-share markets [7][30][32] - The trend of increasing capital increases for pharmaceutical companies is evident, particularly among Hong Kong-listed firms [33] Summary by Sections Innovation Chain Improvement - The research indicates that the innovative drug R&D environment in China is becoming more favorable, with supportive policies leading to a rebound in investment [6][23] Financing and IPO Trends - The report highlights a resurgence in IPOs for innovative drug companies, with 62 companies listed in Hong Kong since 2019 and a significant increase in fundraising [26][30] - The reopening of the listing channel for unprofitable companies on the Sci-Tech Innovation Board is expected to provide additional funding sources for innovative drug firms [28][30] BD Payments as a Funding Source - The report notes that upfront payments from business development (BD) have become a major source of funding for R&D, with a significant amount of $1.73 billion in Q2 2025, surpassing the total biopharmaceutical financing amount [9][40] Increased Capital Increases - Pharmaceutical companies are increasingly raising capital through share issuances, particularly in the Hong Kong market, to strengthen their cash positions [33] Investment Opportunities - The report suggests focusing on companies with healthy cash flows and innovative capabilities, particularly in breakthrough therapies and technologies [49]

Core Insights - China is making significant progress in becoming a strong nation in intellectual property (IP) during the 14th Five-Year Plan period, focusing on enhancing innovation capabilities and the effective utilization of IP [1][2]. Group 1: Innovation Strength - China is transitioning from being a major importer of IP to a creator of IP, with a notable increase in high-value core patents in strategic emerging sectors such as 5G, AI, aerospace, and new energy vehicles [2]. - As of June 2023, the number of high-value invention patents per 10,000 people reached 15.3, surpassing the 12 target set for the 14th Five-Year Plan [2]. - There are 524,000 domestic enterprises holding effective invention patents, totaling 3.727 million patents, which accounts for 74.4% of the national total, reflecting a 6.1 percentage point increase from the end of the 13th Five-Year Plan [2]. Group 2: Patent Growth by Sector - The top three sectors for growth in effective invention patents are information technology management methods, computer technology, and medical technology, with year-on-year growth rates of 34.1%, 22.7%, and 19.8% respectively, significantly outpacing the average growth rate [3]. - Patent-intensive industries contributed 16.87 trillion yuan in added value in 2023, representing 13.04% of China's GDP [3]. Group 3: Utilization and Commercialization - The transformation of IP into productive forces is emphasized, with initiatives to promote patent commercialization leading to a rise in the industrialization rate of enterprise invention patents from 44.9% in 2020 to 53.3% by 2024 [4]. - The annual import and export total of IP usage fees is projected to increase from 319.44 billion yuan in 2020 to 398.71 billion yuan by 2024 [4]. - The value of Chinese brands among the global top 5,000 reached 1.76 trillion USD, ranking second worldwide [4]. Group 4: International Cooperation - China has established IP cooperation with over 80 countries and regions, with a patent examination highway covering 84 countries, enhancing the innovation environment for foreign enterprises in China [5]. - The country has provided extensive guidance and consultation services to outbound enterprises, helping to reduce litigation costs by 1.32 billion yuan and recover economic losses of 38.04 billion yuan [5]. - China is also promoting green innovation through international cooperation, contributing 12,000 green technologies to the World Intellectual Property Organization [5].

Market Performance - On July 17, A-shares saw collective gains across the three major indices, with the Shanghai Composite Index rising by 0.37% to close at 3516.83 points, the Shenzhen Component Index increasing by 1.43% to 10873.62 points, and the ChiNext Index up by 1.76% to 2269.33 points [1] - The total trading volume in the Shanghai and Shenzhen markets reached 15.394 trillion yuan, an increase of 973 billion yuan compared to July 16 [1] - A total of 3536 stocks rose, with 66 hitting the daily limit up, while 1611 stocks declined, with 6 hitting the daily limit down [1] Sector Performance - Most industry sectors experienced gains, with aerospace, biopharmaceuticals, electronic components, medical services, communication equipment, consumer electronics, energy metals, and chemical pharmaceuticals leading the increases, while precious metals saw the largest declines [1] - The technology sector showed strong performance, driven by Nvidia's easing of chip restrictions, which has opened up market opportunities and is expected to lead to a systematic restructuring of the entire AI-related industry chain [1] Military Industry Insights - The military sector experienced a strong rally, attributed to two main factors: a significant arms purchase order from a Middle Eastern country and the overlap of military concepts with the low-altitude economy, which is being actively developed as a new economic growth point [2] - The military sector has rebounded for two consecutive days, but caution is advised for those considering chasing prices, suggesting waiting for a pullback for better opportunities [2] Local Stock Performance - In Hunan stocks, 96 out of 146 stocks rose, with Guangxin Technology, Huarui Precision, and Wuxin Tunnel Equipment all increasing by over 8% [3] - Guangxin Technology's half-year earnings forecast indicates a net profit attributable to shareholders of 90 million to 100 million yuan, representing a year-on-year growth of 78.65% to 98.50%, driven by sustained demand in the downstream market [3] - Huarui Precision reported a net profit of 29.224 million yuan for Q1 2025, with a year-on-year growth rate of 70% [3] - Wuxin Tunnel Equipment announced a major asset restructuring plan to acquire 100% equity of two companies, with efforts underway to complete audits and respond to inquiries from intermediaries [3]

Market Overview - The Hong Kong stock market indices showed a narrow range of fluctuations, with a sharp drop in the last trading session [1] - The Hang Seng Index and the Hang Seng China Enterprises Index fell slightly by 0.08% and 0.09% respectively, while the Hang Seng Tech Index rose by 0.56% [2][3] Sector Performance - Large tech stocks had mixed performances, with Meituan rising over 1%, while Baidu and Xiaomi fell by over 3% and 2% respectively [2] - The biopharmaceutical sector surged, with notable gains from companies like CanSino Biologics, which rose by 14.5%, and others like Innovent Biologics and BeiGene, which increased by over 10% [5][6] - Semiconductor, military, automotive, and Apple concept stocks were active, with CITIC Securities and China International Capital Corporation showing significant gains in the afternoon session [4] Biopharmaceutical Sector Insights - The biopharmaceutical sector led the market, with CanSino Biologics up 14.5%, Innovent Biologics and BeiGene up over 10%, and several others showing strong performance [5][6] - Goldman Sachs noted that the Chinese biotech industry is undergoing a structural revaluation, indicating that the current surge is not just a short-term rebound [6] Entertainment and Media Stocks - The entertainment sector was active, with companies like Bigo Group and Damai Entertainment rising over 10% and 8% respectively [7][8] Military and Automotive Stocks - Military stocks saw significant increases, with companies like Xian Aircraft and AVIC rising over 4% and 3% respectively [9] - Automotive stocks also performed well, with Li Auto rising over 9% and several other manufacturers showing gains [10] Renewable Energy Sector - The solar energy sector saw gains, with Fuyao Glass rising over 4% and several other companies also showing positive movement [11] Education Sector - The education sector faced declines, with companies like Think Tank Education dropping nearly 5% [12] Metals and Mining Sector - The copper and gold sectors experienced declines, with companies like Jihai Resources falling over 7% and several others dropping significantly [13] Future Outlook - Analysts suggest caution regarding potential tactical adjustments in the Hong Kong market in early Q3, but see opportunities for buying during fluctuations as the market may improve with progress in US-China trade talks and potential interest rate cuts [13]

金十数据7月17日讯，港股今日冲高回落，尾盘再度倒跌。恒指高开29点报24547点，升幅一度扩大至 154点高见24672点，但高位抛压再度涌现，大市一度由升转跌。午后走势疲软，尾盘跌幅扩大，逼近早 盘低位。截至收盘，恒指收跌0.08%；科指收涨0.56%，恒指大市成交额2364.1亿元。盘面上，影视、汽 车零件、半导体股走强，生物医药股延续强势再度爆发；稀土概念、贵金属股连续两日回调，新消费概 念股大跌。个股方面，理想汽车(02015.HK)涨超9%，中国生物制药(01177.HK)涨超6%，地平线机器人 (09660.HK)涨近5%；周大福(01929.HK)跌超3.5%，百度(09888.HK)跌超3%。 港股收评：恒指收跌0.08% 生物医药股全天强势 ...

Core Viewpoint - The judicial auction of 58.607 million shares of Tsinghua Unigroup (启迪药业) has resulted in a significant change in the company's control, with Hunan Sailoxian Management Consulting Partnership winning the bid at 1.007 billion yuan, potentially altering the ownership structure of the company [2][3][4]. Group 1: Auction Details - The auction attracted over 400,000 online viewers and involved eight competitive buyers, culminating in 138 rounds of bidding and 107 extensions [2][3]. - Hunan Sailoxian, established on June 19, 2025, with a registered capital of 400 million yuan, won the auction, with its major shareholder being Jiang Xin, who also leads Hunan Hengchang Pharmaceutical [3]. Group 2: Ownership Changes - If the auction is finalized, Tsinghua Unigroup will completely exit its shareholder position, reducing its voting rights from 26.37% to 1.90%, while Hunan Sailoxian will become the largest shareholder with a 24.47% stake [3][4]. - The second-largest shareholder, Hengyang Hongxiang State Investment Group, holds 19.11% of the shares, indicating a close competition between state-owned and private entities [4]. Group 3: Legal Context - The auction stems from a financial dispute between Tsinghua Unigroup and the Agricultural Bank of China, leading to the shares being put up as collateral [2][3]. - Tsinghua Unigroup has previously engaged in legal action against Hengchang Pharmaceutical for trademark infringement, raising questions about future legal strategies post-control change [5].

Group 1 - The core viewpoint is that the national medical insurance fund in China is operating safely and steadily in 2024, with both total income and expenditure showing a year-on-year growth trend [1] - The cumulative balance of employee medical insurance and urban-rural resident medical insurance reached 4.49 trillion and 818.3 billion respectively, indicating overall stable fund operations [1] - The insured population remains stable at over 95%, with employee medical insurance participants increasing by 2.3%, income growing by 3.5%, and expenditure rising by 7.6% [1] Group 2 - Resident medical insurance income increased by 5.78%, while expenditure grew by 1.9%, reflecting a healthy financial environment for the sector [1] - The coordinated development of the "three medicines" (medical, medicine, and health) has significantly improved governance, providing a stable payment environment for the biopharmaceutical industry [1] - There is a noticeable trend of innovation and internationalization in the industry, with a focus on innovative drugs and medical consumption opportunities, as well as breakthroughs in technologies like restructured collagen new materials [1] Group 3 - The biopharmaceutical ETF tracks the CS Biomedicine Index, which is compiled by China Securities Index Co., Ltd., selecting listed companies in biotechnology, medical devices, and medical services to reflect the overall performance of the biopharmaceutical sector [1] - The index is characterized by strong industry representation and growth potential, effectively reflecting the development trends of the biopharmaceutical industry [1] - Investors without stock accounts can consider the Guotai CSI Biopharmaceutical ETF Connect A (006756) and Connect C (006757) [1]